RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Liquidia Technologies today announced that it will present findings from preclinical proof-of-concept studies conducted with its next generation, multivalent pneumococcal vaccine that is based on the company’s novel PRINT® (Particle Replication In Non-Wetting Templates) technology. Results from these studies will be presented at the 32nd European Society for Paediatric Infectious Diseases (ESPID) Annual Meeting being held May 6-10, 2014 in Dublin, Ireland. ESPID 2014 will bring an estimated 3000 international researchers and clinicians who are committed to the treatment and prevention of infectious disease in children.
Help employers find you! Check out all the jobs and post your resume.
